1 / 2

D’après Alberu J. et al. Transplantation 2011

Taux de tumeurs malignes pour 100 patients dans les groupes sirolimus (SRL) et anticalcineurines (CNI) : étude CONVERT. D’après Alberu J. et al. Transplantation 2011. Schéma de l’étude SILVER. Diagnostic d’HCC. Transplantation hépatique (histologie).

nolcha
Download Presentation

D’après Alberu J. et al. Transplantation 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Taux de tumeurs malignes pour 100 patients dans les groupes sirolimus (SRL) et anticalcineurines (CNI) : étude CONVERT D’après Alberu J. et al. Transplantation 2011

  2. Schéma de l’étude SILVER Diagnostic d’HCC Transplantation hépatique (histologie) 4-6 semaines sans inhibiteur de mTOR Randomisation Groupe 2 Groupe 1 Protocole IS sans inhibiteur de mTOR Protocole IS comportant du sirolimus Survie sans progression (analyse des événements) IS : immunosuppression D’aprèsSchnitzbauer A.A. et al.BMC 2010

More Related